RIA
NKTR icon

Realta Investment Advisors’s Nektar Therapeutics NKTR Stock Holding History

Realta Investment Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-20
Closed -$6K – 1002
2019
Q4 		$6K Hold
20
– – ﹤0.01% 1300
2019
Q3 		$5K Sell
20
-109
-84% -$40K ﹤0.01% 1329
2019
Q2 		$70K Buy
129
+99
+330% +$49.6K 0.02% 597
2019
Q1 		$15K Buy
+30
New +$17.8K 0.01% 832

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Realta Investment Advisors's NKTR Position: Q1 2020 in Review

Realta Investment Advisors sold out of Nektar Therapeutics (NKTR) in Q1 2020, closing a stake of 20 shares — an estimated $6K sold.

Realta Investment Advisors first reported a position in NKTR in Q1 2019 and held it in 4 quarters. The position peaked at $70K in Q2 2019. 245 funds tracked by Wall St. Rank hold NKTR as of Q1 2020.

  • Realta Investment Advisors reported no remaining Nektar Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Realta Investment Advisors sold 20 Nektar Therapeutics shares in Q1 2020, an estimated $6K.
  • Realta Investment Advisors first reported a position in Nektar Therapeutics in Q1 2019 and held it in 4 quarters.
  • Realta Investment Advisors's Nektar Therapeutics position peaked at $70K in Q2 2019.
  • 245 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2020.

Based on Realta Investment Advisors's 13F filing for Q1 2020, filed 23 Apr 2020.